# Novo Nordisk A/S: Phase 1 study in Overweight, Obesity (60 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication |
| NCT ID | NCT07868354 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Overweight; Obesity; Type 2 Diabetes |
| Intervention types | drug |
| Target enrollment | 60 |
| Site countries | United States |
| Posted | 2026-10-09 |
| Planned start | 2026-10-08 |
| Event | Newly registered study |
| Event date | 2026-10-09 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07868354). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.